Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CCW 702 |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 1 | US | 17 Jul 2020 | |
Metastatic castration-resistant prostate cancer | Phase 1 | US | 17 Jul 2020 | |
Prostatic Cancer | Phase 1 | - | - |